Allakos Inc ALLK:NASDAQ

Last Price$79.60NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/01/21

Today's Change+1.25(1.60%)
Bid (Size)$77.83 (1)
Ask (Size)$82.98 (1)
Day Low / High$78.40 - 81.63
Volume618.7 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 12/01/2021

 

Allakos Inc ( NASDAQ )

Price: $79.60
Change: +1.25 (1.60%)
Volume: 618.7 K
4:00PM ET 12/01/2021
 
 

Apellis Pharmaceuticals Inc ( NASDAQ )

Price: $43.46
Change: +1.38 (3.28%)
Volume: 1.6 M
4:00PM ET 12/01/2021
 
 

Karuna Therapeutics Inc ( NASDAQ )

Price: $123.05
Change: -4.85 (3.79%)
Volume: 1.00
4:00PM ET 12/01/2021
 
 

Reata Pharmaceuticals Inc ( NASDAQ )

Price: $91.06
Change: +5.46 (6.38%)
Volume: 632.6 K
4:00PM ET 12/01/2021
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $36.47
Change: -1.59 (4.18%)
Volume: 706.4 K
4:00PM ET 12/01/2021
 

Read more news Recent News

Allakos Expands Development of Lirentelimab Into Dermatitis, Hives, Asthma
7:54AM ET 11/30/2021 MT Newswires

Allakos (ALLK) said Tuesday it is expanding its development program for lirentelimab into dermatitis, asthma, and chronic spontaneous urticaria. The...

--Morgan Stanley Adjusts Price Target on Allakos to $86 From $88, Maintains Equal-Weight Rating
1:30PM ET 11/10/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Morgan Stanley Starts Allakos at Equal-Weight With $88 Price Target
6:28AM ET 8/26/2021 MT Newswires

Allakos (ALLK) has an average rating of outperform and price targets ranging from $36 to $230, according to analysts polled by Capital IQ. (MT Newswires...

Cowen Initiates Coverage on Allakos With Outperform Rating
8:08AM ET 7/15/2021 MT Newswires

Allakos (ALLK) has an average rating of outperform and price targets ranging from $36 to $230, according to analysts polled by Capital IQ. (MT Newswires...

View all Commentary and Analysis

Tracking Baker Brothers Portfolio - Q2 2021 Update
12:54AM ET 10/05/2021 Seeking Alpha

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
6:39AM ET 8/06/2021 Seeking Alpha

Tracking Baker Brothers Portfolio - Q1 2021 Update
7:50AM ET 7/08/2021 Seeking Alpha

Allakos: Prevalence Data Shows A Large Undiagnosed Market
7:42AM ET 3/21/2021 Seeking Alpha

Company Profile

Business DescriptionAllakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA. View company web site for more details
Address975 Island Drive
Redwood City, California 94065
Phone+1.650.597.5002
Number of Employees62
Recent SEC Filing11/30/20218-K
Chief Executive Officer & DirectorRobert Alexander
President & Chief Operating OfficerAdam L. Tomasi
Chief Financial OfficerHarlan Baird Radford
Chief Medical OfficerCraig Paterson

Company Highlights

Price Open$78.47
Previous Close$79.60
52 Week Range$75.41 - 157.98
Market Capitalization$4.3 B
Shares Outstanding54.3 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.13
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-37.16%

Analyst Ratings as of 08/26/2021

Buy
8
Overweight
0
Hold
2
Underweight
0
Sell
2
Consensus RecommendationConsensus Icon
Powered by Factset